Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.53 |
| ▸ | HRH1 | P35367 | 1/20 | 0.53 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1872669 | 0.99 | HRH3 (0.55) | HRH3HRH1HRH4MEN1KMT2A | |
| SCHEMBL1880093 | 0.87 | HRH3 (0.51) | HRH3HRH1HRH4MEN1KMT2A | |
| SCHEMBL1871690 | 0.86 | HRH3 (0.55) | HRH3HRH1HRH4MEN1KMT2A | |
| SCHEMBL1875525 | 0.83 | HRH3 (0.60) | HRH3HRH1HRH4MEN1KMT2A | |
| SCHEMBL12333846 | 0.83 | HRH3 (0.51) | HRH3HRH1HRH4MEN1KMT2A | |
| SCHEMBL1877465 | 0.81 | HRH3 (0.49) | HRH3HRH1HRH4MEN1KMT2A | |
| SCHEMBL1876359 | 0.80 | HRH3 (0.51) | HRH3HRH1HRH4KCNH2HTR3A | |
| SCHEMBL1882951 | 0.80 | HRH3 (0.56) | HRH3HRH1HRH4MEN1KMT2A | |
| SCHEMBL1883043 | 0.79 | HRH3 (0.58) | HRH3HRH1HRH4KCNH2HTR3A | |
| SCHEMBL598706 | 0.76 | SIGMAR1 (0.60) | HRH3HRH1HRH4KCNH2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1988777-B1 | PYRAZOLES FOR THE TREATMENT OF OBESITY AND OTHER CNS DISORDERS | ATHERSYS INC (US) | 2011-09-21 | — | — | EP | claimed |
| US-7897634-B2 | Pyrazoles for the treatment of obesity and other CNS disorders | ATHERSYS, INC. (US) | 2011-03-01 | — | — | US | claimed |
| US-20070197526-A1 | Pyrazoles for the treatment of obesity and other CNS disorders | ATHERSYS, INC. | 2007-08-23 | — | — | US | claimed |
| EP-1988777-B1 | PYRAZOLES FOR THE TREATMENT OF OBESITY AND OTHER CNS DISORDERS | ATHERSYS INC (US) | 2011-09-21 | — | — | EP | disclosed |
| US-7981896-B2 | Pyrazoles for the treatment of obesity and other CNS disorders | ATHERSYS, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20110112088-A1 | PYRAZOLES FOR THE TREATMENT OF OBESITY AND OTHER CNS DISORDERS | BENNANI YOUSSEF L | 2011-05-12 | — | — | US | disclosed |
| US-7897634-B2 | Pyrazoles for the treatment of obesity and other CNS disorders | ATHERSYS, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20070197526-A1 | Pyrazoles for the treatment of obesity and other CNS disorders | ATHERSYS, INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112088-A1 | PYRAZOLES FOR THE TREATMENT OF OBESITY AND OTHER CNS DISORDERS | GPR119, HCRTR2, HCRTR1 | HRH3 986/4885HRH1 1390/4885HRH4 647/4885 |
| US-20070197526-A1 | Pyrazoles for the treatment of obesity and other CNS disorders | HRH3, HRH4, HRH2 | HRH3 1/4885HRH1 4/4885HRH4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.